Medipharm Labs Increases Bought Deal To $29.0 Million
Medipharm Labs (TSX: LABS) has increased the size of the bought deal financing announced last night. Originally pegged at $20.0 million, the financing has now increased to $29.0 million.
The financing, lead by Cantor Fitzgerald, will see 50.0 million units of the company sold at a price of $0.58 per unit. Each unit contains one common share and one common share purchase warrant, with each warrant valid for a period of two years from the date of issuance with a conversion price of $0.70 per share.
An over-allotment option has also been issued, which is valid for a period of 30 days following the close of the transaction.
Proceeds from the financing are to be used to fund product development, pharmaceutical registrations, R&D, sales and marketing, as well as working capital and general corporate purposes.
The financing is slated to close March 5, 2021.
Medipharm Labs last traded at $0.68 on the TSX.
.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.